Aveo spins a silver lining in failed trial of kidney cancer drug Fotivda

The addition of Bristol Myers Squibb’s Opdivo to a low dose of Aveo Oncology’s Fotivda failed to extend the time before tumor progression or death in kidney cancer patients who had tried an immune checkpoint inhibitor (ICI).